bluebird bio Inc (BLUE)

76.25
0.85 1.10
NASDAQ : Health Care
Prev Close 77.10
Open 77.65
Day Low/High 74.95 / 78.70
52 Wk Low/High 35.37 / 169.16
Volume 664.83K
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 37.30M
Market Cap 2.88B
EPS -4.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product Under Amended Study Protocol In HGB-206 Phase 1 Study Of Patients With Severe Sickle Cell Disease

Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product Under Amended Study Protocol In HGB-206 Phase 1 Study Of Patients With Severe Sickle Cell Disease

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of...

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Bluebird Bio Looks Set to Soar Upward

Bluebird Bio Looks Set to Soar Upward

Meal worms not needed to give it strength.

Bluebird Bio To Present At The 35th Annual J.P. Morgan Healthcare Conference

Bluebird Bio To Present At The 35th Annual J.P. Morgan Healthcare Conference

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced today that...

Short Interest In Bluebird Bio Moves 11.2% Lower

Short Interest In Bluebird Bio Moves 11.2% Lower

The most recent short interest data has been released for the 12/15/2016 settlement date, which shows a 998,903 share decrease in total short interest for bluebird bio Inc , to 7,944,807, a decrease of 11.17% since 11/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

Jim Cramer favors UnitedHealth over Cerner, and U.S. Concrete more than Cemex.

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Get used to some down days, says Jim Cramer, but don't lose sight of the success for financial stocks.

Bluebird Bio And Apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

Bluebird Bio And Apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer and apceth Biopharma...

Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product In Northstar-2 (HGB-207) Phase 3 Trial Of Patients With Transfusion-Dependent ß-Thalassemia

Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product In Northstar-2 (HGB-207) Phase 3 Trial Of Patients With Transfusion-Dependent ß-Thalassemia

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of...

Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers

Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers

Shares tanked Wednesday on little more than a two-sentence comment from the president-elect.

Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High

Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High

The Dow Jones Industrial Average's winning streak continued after closing higher for the 18th time in 22 sessions. The S&P 500 also hit a new record high.

Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally

Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally

The S&P 500 and Dow Jones Industrial Average trade at session highs early Wednesday afternoon as a broad rally overshadows a slump in health care stocks.

S&P 500 and Dow Reverse Losses to Post Intraday Records

S&P 500 and Dow Reverse Losses to Post Intraday Records

The S&P 500 reverses an earlier loss to post small gains, trading at a new intraday record, thanks to broad gains across all sectors save for health care.

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

There's little to substantiate the president-elect's claim that he will bring drug prices down, but biotech investors are trading anyway.

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an...

Bluebird Bio Announces Proposed Public Offering Of Common Stock

Bluebird Bio Announces Proposed Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an...

Bluebird Bio Provides Updates On HSC Gene Therapy Programs

Bluebird Bio Provides Updates On HSC Gene Therapy Programs

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, provided updates across...

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting

Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced the...

Bluebird Bio Announces Management Appointments

Bluebird Bio Announces Management Appointments

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced two new...

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Cramer wonders if this market has gotten too enthusiastic for the Trump agenda.

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.

Bluebird Bio Announces Interim Phase 1 Dose Escalation Data For Its Anti-BCMA CAR T Product Candidate In Patients With Relapsed/Refractory Multiple Myeloma

Bluebird Bio Announces Interim Phase 1 Dose Escalation Data For Its Anti-BCMA CAR T Product Candidate In Patients With Relapsed/Refractory Multiple Myeloma

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim...

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

How Buying Blue Apron Ahead of any IPO Could Leave You Blue

How Buying Blue Apron Ahead of any IPO Could Leave You Blue

Remembering old ticker missteps ahead of any IPOs by unicorns.

Bluebird Bio To Present New Data From Novel Anti-BCMA CAR T Cell Therapy Bb2121 At EORTC-NCI-AACR Molecular Targets And Cancer Therapies Symposium

Bluebird Bio To Present New Data From Novel Anti-BCMA CAR T Cell Therapy Bb2121 At EORTC-NCI-AACR Molecular Targets And Cancer Therapies Symposium

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim...

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.

Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting

Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that data...

TheStreet Quant Rating: D (Sell)